AVALON GLOBOCAR/SH SH (OTCMKTS: AVCO) is one of 26 public companies in the “Management consulting services” industry, but how does it compare to its peers? We will compare AVALON GLOBOCAR/SH SH to similar businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.
This is a summary of current ratings and recommmendations for AVALON GLOBOCAR/SH SH and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AVALON GLOBOCAR/SH SH||0||0||0||0||N/A|
|AVALON GLOBOCAR/SH SH Competitors||123||403||581||30||2.46|
Insider & Institutional Ownership
65.4% of shares of all “Management consulting services” companies are owned by institutional investors. 75.0% of AVALON GLOBOCAR/SH SH shares are owned by insiders. Comparatively, 13.3% of shares of all “Management consulting services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares AVALON GLOBOCAR/SH SH and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AVALON GLOBOCAR/SH SH||$1.08 million||-$3.46 million||-55.00|
|AVALON GLOBOCAR/SH SH Competitors||$993.84 million||$66.10 million||15.85|
AVALON GLOBOCAR/SH SH’s peers have higher revenue and earnings than AVALON GLOBOCAR/SH SH. AVALON GLOBOCAR/SH SH is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
AVALON GLOBOCAR/SH SH has a beta of -5.48, meaning that its stock price is 648% less volatile than the S&P 500. Comparatively, AVALON GLOBOCAR/SH SH’s peers have a beta of 0.62, meaning that their average stock price is 38% less volatile than the S&P 500.
This table compares AVALON GLOBOCAR/SH SH and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AVALON GLOBOCAR/SH SH||-365.09%||-81.16%||-44.88%|
|AVALON GLOBOCAR/SH SH Competitors||-18.16%||-37.30%||-2.67%|
AVALON GLOBOCAR/SH SH peers beat AVALON GLOBOCAR/SH SH on 9 of the 10 factors compared.
AVALON GLOBOCAR/SH SH Company Profile
Avalon GloboCare Corp., together with its subsidiaries, engages in integrating and managing healthcare services and resources in the United States. It provides medical related consulting services and develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology, as well as rehabilitation medicine. The company also develops proprietary diagnostic and therapeutic products leveraging exosome technology; and markets and distributes proprietary exosome isolation systems and related products to hospitals, as well as provides development services for hospitals. In addition, it owns and operates real property. The company has a strategic partnership Weill Cornell Medical College to co-develop technologies and bio-production of chimeric antigen receptor-T Therapy. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.
Receive News & Ratings for AVALON GLOBOCAR/SH SH Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVALON GLOBOCAR/SH SH and related companies with MarketBeat.com's FREE daily email newsletter.